- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- Trastuzumab, Tucatinib
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 34 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1681–1704
of 3,056
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Peritoneal Neoplasms
- Interventions
- nanoparticulate paclitaxel
- Drug
- Lead sponsor
- CritiTech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • Wichita, Kansas • Oklahoma City, Oklahoma
- Conditions
- Lynch Syndrome, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Family Characteristics, Genetic Predisposition
- Interventions
- online cancer risk assessment, Usual care
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 18,623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Colon Cancer, Rectal Cancer
- Interventions
- CoFactor and 5FU
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 5
- States / cities
- La Jolla, California • Sacramento, California • San Diego, California + 2 more
- Conditions
- Pain, Metastatic Breast Cancer, Prostate Cancer, Colorectal Cancer
- Interventions
- Quell, Sham Quell
- Device
- Lead sponsor
- Scripps Translational Science Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Colorectal Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer
- Interventions
- Exercise Program
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Colorectal Cancer
- Interventions
- Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 17
- States / cities
- Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
- Conditions
- Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
- Interventions
- BCA101, Pembrolizumab
- Drug
- Lead sponsor
- Bicara Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 15
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 10 more
- Conditions
- Colorectal Cancer, Ovarian Carcinoma, Appendix Cancer, Peritoneal Metastases
- Interventions
- CRS-HIPEC + LSTA1, CRS-HIPEC alone
- Drug · Procedure
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Colorectal Cancer Screening
- Interventions
- COLON Capsule endoscopy, Computed Tomographic Colonography
- Device
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 13
- States / cities
- Mobile, Alabama • Jacksonville, Florida • Chicago, Illinois + 8 more
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer
- Interventions
- cyclophosphamide, poly ICLC, hepatic artery embolization, 3-dimensional conformal radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Adenomatous Polyp, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage I Colon Cancer, Stage I Rectal Cancer, Stage IIA Colon Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
- Interventions
- erlotinib hydrochloride, placebo, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 3
- States / cities
- Long Beach, California • Orange, California • Chicago, Illinois
- Conditions
- Colorectal Cancer, Head and Neck Cancer
- Interventions
- Urelumab, Cetuximab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Stanford, California • Chicago, Illinois • Baltimore, Maryland + 4 more
- Conditions
- Colon Cancer, Rectal Cancer
- Interventions
- educational intervention, questionnaire administration
- Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Colorectal Cancer, Cancer of Gastrointestinal Tract
- Interventions
- Abraxane
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer
- Interventions
- Etrumadenant, Zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Stomach Cancer, Esophageal Cancer
- Interventions
- MI-Walk Intervention, Physical Activity Education Pamphlet
- Behavioral
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- Ann Arbor, Michigan • Brighton, Michigan • Canton, Michigan + 2 more
- Conditions
- Inflammation, Prevention and Control, Colonic Neoplasms, Diet, Insulin
- Interventions
- LIFE
- Dietary Supplement
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 35 Years to 75 Years · Male only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2018
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Colorectal Cancer
- Interventions
- Colorectal Cancer Screening Decision Aid, Control Group
- Behavioral
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Lumberton, North Carolina
- Conditions
- Colorectal Cancer
- Interventions
- adenoma vs no adenoma, colonoscopy vs no colonoscopy, survey and expert panel
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 75 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- San Diego, California • West Los Angeles, California
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- CY, GVAX, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Pathologic Stage 0 Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Best Practice, Biospecimen Collection, Endoscopic Procedure, Fecal Microbiota Transplantation, Infliximab, Laboratory Biomarker Analysis, Prednisone, Vedolizumab
- Other · Procedure · Biological + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ulcerative Colitis
- Interventions
- Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 9
- States / cities
- Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more
- Conditions
- Metastases, Colorectal Neoplasms, Colorectal Carcinoma
- Interventions
- Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, Leucovorin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 879 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey